연구성과로 돌아가기

2023 연구성과별 연구자 정보 (36 / 2675)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
A multi-band study and exploration of the radio wave-γ-ray connection in 3C 84 Tornikoski, M. Tornikoski, M 9 Aalto Univ, Metsahovi Radio Observ, Metsahovintie 114, Kylmala 02540, Finland gfparaschos@mpifr-bonn.mpg.de;
A multi-band study and exploration of the radio wave-γ-ray connection in 3C 84 Kiehlmann, S. Kiehlmann, S 10 Fdn Res & Technol Hellas, Inst Astrophys, Iraklion 71110, Greece G-7253-2019 Kiehlmann, Sebastian gfparaschos@mpifr-bonn.mpg.de;
A multi-band study and exploration of the radio wave-γ-ray connection in 3C 84 Kiehlmann, S. Kiehlmann, S 10 Univ Crete, Dept Phys, Iraklion 70013, Greece G-7253-2019 Kiehlmann, Sebastian gfparaschos@mpifr-bonn.mpg.de;
A multi-band study and exploration of the radio wave-γ-ray connection in 3C 84 Readhead, A. C. S. Readhead, ACS 11 CALTECH, Owens Valley Radio Observ, Pasadena, CA 91125 USA gfparaschos@mpifr-bonn.mpg.de;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Kim, Seok Jin Kim, SJ 1 교신저자 Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med,Dept Internal Med, Seoul, South Korea I-6927-2019 KIM, JIN kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Kim, Seok Jin Kim, SJ 1 교신저자 Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, 81 Irwon Ro Gangnam, Guam 06351, South Korea I-6927-2019 KIM, JIN kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Do, Young Rok Do, YR 2 Dongsan Med Ctr, Daegu, South Korea kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Lee, Ho-Sup Lee, HS 3 Kosin Univ, Gospel Hosp, Busan, South Korea kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Lee, Won-Sik Lee, WS 4 Inje Univ, Busan Paik Hosp, Busan, South Korea kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Kong, Jee Hyun Kong, JH 5 Yonsei Univ, Wonju Severance Christian Hosp, Dept Internal Med, Div Oncol Hematol,Wonju Coll Med, Wonju, South Korea kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Kong, Jee Hyun Kong, JH 5 Yonsei Univ, Inst Convergence Sci, Ctr Evidence Based Med, Seoul, South Korea kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Kwak, Jae-Yong Kwak, JY 6 Jeonbuk Natl Univ, Med Sch, Dept Internal Med, Jeonju, Jeonbuk, South Korea kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Eom, Hyeon-Seok Eom, HS 7 Natl Canc Ctr, Dept Internal Med, Hematol Oncol Clin, Goyang, South Korea kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Moon, Joon Ho Moon, JH 8 Kyungpook Natl Univ Hosp, Daegu, South Korea kstwoh@skku.edu;drydh1685@hotmail.com;
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study Yi, Jun Ho Yi, JH 9 Chung Ang Univ Hosp, Seoul, South Korea GXZ-8144-2022 Yi, Jun Ho kstwoh@skku.edu;drydh1685@hotmail.com;
페이지 이동: